Sara Durland-Busbice

Author

Also Known As

S Durland-Busbice, Sara Durland-Busbice, Sara DurlandBusbice

Publications

151

Citations

H-Index

Concepts

All Affiliations

Sara Durland-Busbice is an author at Florida Cancer Specialists & Research Institute specializing in pharmacology, cancer therapeutics, and medicine.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	11
2	Pharmacology	1	1	11
3	Cancer Cell Biology	1	1	11
4	Cancer Therapeutics	1	1	11
5	Molecular Oncology	1	1	11

Sara Durland-Busbice

Publications

111

Citations

H-Index

Page 1

	Year	Citations
Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells Susan E. Pratt, Sara Durland-Busbice, Robert L. Shepard, Clinical Cancer Research	2013	100
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS). Mrinal M. Gounder, Noboru Yamamoto, Manish R. Patel, Journal of Clinical Oncology Mdm2-amplified DiseaseAdvanced/metastatic LiposarcomaBi 907828Phase Ia/ibMedicine	2022	11

Page 1